Hedgehog pathway aberrations and gastric cancer; evaluation of prognostic impact and exploration of therapeutic potentials

Tumor Biology

Volumn 36, Issue 3, 2015, Pages 1367-1374

  Abdel Rahman, Omar ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Gastric cancer; Hedghog; Vismodegib

Indexed keywords

ANTINEOPLASTIC AGENT; SONIC HEDGEHOG PROTEIN;

ANIMAL; DRUG EFFECTS; HUMAN; METABOLISM; PROGNOSIS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; HEDGEHOG PROTEINS; HUMANS; PROGNOSIS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84930919608     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3216-6     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
3. Fitzgerald R, Hardwick R, Huntsman D. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010;47:436–44.
4. Abdel-Rahman O. Insulin-like growth factor pathway aberrations and gastric cancer; evaluation of prognostic significance and assessment of therapeutic potentials. Med Oncol. 2015;32(1):431. doi:10.1007/s12032-014-0431-8.
5. Kordes S, Cats A, Meijer SL, van Laarhoven HW. Targeted therapy for advanced esophagogastric adenocarcinoma. Crit Rev Oncol Hematol. 2014;90:68–76.
6. Abdel-Rahman O. Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications. Expert Rev Anticancer Ther 2014;(0):1–11.
7. Abdel-Rahman O. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects. Crit Rev Oncol Hematol. 2015;93(1):18–27.
8. Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 2001;15:3059–87.
9. Riddle RD, Johnson RL, Laufer E, Tabin C. Sonic hedgehog mediates the polarizing activity of the ZPA. Cell. 1993;75:1401–16.
10. Echelard Y et al. Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. Cell. 1993;75:1417–30.
11. Stecca B, Ruiz I, Altaba A. Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals. J Mol Cell Biol. 2010;2:84–95.
12. Wang B, Fallon JF, Beachy PA. Hedgehog-regulated processing of Gli3 produces an anterior/posterior repressor gradient in the developing vertebrate limb. Cell. 2000;100:423–34.
13. Kim JH, Choi YJ, Lee SH, Shin HS, Lee IO, Kim YJ, et al. Effect of Helicobacter pylori infection on the sonic hedgehog signaling pathway in gastric cancer cells. Oncol Rep. 2010;23(6):1523–8.
14. Yang L, Huang S, Bian Y, Ma X, Zhang H, Xie J. Identification of signature genes for detecting hedgehog signaling activation in gastric cancer. Mol Med Rep. 2010;3(3):473.
15. Yan R, Peng X, Yuan X, Huang D, Chen J, Lu Q, et al. Suppression of growth and migration by blocking the hedgehog signaling pathway in gastric cancer cells. Cell Oncol. 2013;36(5):421–35.
16. Lee SJ, Do IG, Lee J, Kim KM, Jang J, Sohn I, et al. Gastric cancer (GC) patients with hedgehog pathway activation: PTCH1 and GLI2 as independent prognostic factors. Target Oncol. 2013;8(4):271–80.
17. Niu Y, Li F, Tang B, Shi Y, Hao Y, Yu P, et al. Clinicopathological correlation and prognostic significance of sonic hedgehog protein overexpression in human gastric cancer. Int J Clin Exp Pathol. 2014;7(8):5144–53. eCollection 2014.
18. Kim JY, Ko GH, Lee YJ, Ha WS, Choi SK, Jung EJ, et al. Prognostic value of sonic hedgehog protein expression in gastric cancer. Jpn J Clin Oncol. 2012;42(11):1054–9.
19. Yoo YA, Kang MH, Lee HJ, Kim BH, Park JK, Kim HK, et al. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res. 2011;71(22):7061–70.
20. Zhang C, Li C, He F, Cai Y, Yang H. Identification of CD44+ CD24+ gastric cancer stem cells. J Cancer Res Clin Oncol. 2011;137(11):1679–86.
21. Song Z, Yue W, Wei B, Wang N, Li T, Guan L, et al. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS One. 2011;6(3):e17687.
22. Wang XD, Inzunza H, Chang H, Qi Z, Hu B, Malone D, et al. Mutations in the hedgehog pathway genes SMO and PTCH1 in human gastric tumors. PLoS One. 2013;8(1):e54415.
23. Fukaya M, Isohata N, Ohta H, Aoyagi K, Ochiya T, Saeki N, et al. Hedgehog signal activation in gastric pit cell and in diffuse-type gastric cancer. Gastroenterology. 2006;131(1):14–29.
24. di Magliano Pasca M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer. 2003;3:903–11.
25. Stanton BZ, Peng LF, Maloof N, Nakai K, Wang X, Duffner JL, et al. A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat Chem Biol. 2009;5(3):154–6. doi:10.1038/nchembio.142.
26. Von Hoff D, Rudin C, LoRusso P, Borad M, Korn R, Heath E, et al. Efficacy data of GDC-0449, a systemic Hedgehog pathway antagonist, in a first-in-human, first-in-class Phase I study with locally advanced, multifocal or metastatic basal cell carcinoma patients; AACR Meeting Abstracts; 2008; 2008. LB-138.
27. Wu X, Ding S, Schultz PG. Compounds and composition as hedgehog pathway modulators. WO2006050351. 2006.
28. Song Y, Tian Y, Zuo Y, Tu JC, Feng YF, Qu CJ. Altered expression of PTCH and HHIP in gastric cancer through their gene promoter methylation: novel targets for gastric cancer. Mol Med Rep. 2013;7(4):1159–68.
29. Yan R, Peng X, Yuan X, Huang D, Chen J, Lu Q, et al. Suppression of growth and migration by blocking the hedgehog signaling pathway in gastric cancer cells. Cell Oncol. 2013;36(5):421–35.
30. Wan J, Zhou J, Zhao H, Wang M, Wei Z, Gao H, et al. Sonic hedgehog pathway contributes to gastric cancer cell growth and proliferation. BioRes Open Access. 2014;3(2):53–9.
31. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.
32. Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366(23):2180–8.
33. Kaye SB, Fehrenbacher L, Holloway R, Amit A, Karlan B, Slomovitz B, et al. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin Cancer Res. 2012;18(23):6509–18.
34. Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res. 2013;19(1):258–67.
35. Cohen DJ, Christos PJ, Sparano JA, Kindler HL, Catenacci DVT, Bekaii-Saab TB, et al. A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: a New York Cancer Consortium led study. J Clin Oncol 2013;31:(4).
36. Kameda C, Nakamura M, Tanaka H, Yamasaki A, Kubo M, Tanaka M, et al. Oestrogen receptor-α contributes to the regulation of the hedgehog signalling pathway in ERα-positive gastric cancer. Br J Cancer. 2010;102(4):738–47.
37. Yoon C, Park DJ, Schmidt B, Thomas NJ, Lee HJ, Kim TS, et al. CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res. 2014;20(15):3974–88.